On 9 July 2001, orphan designation (EU/3/01/044) was granted by the European Commission to Aventis Behring GmbH, Germany, for human alpha-1-proteinase inhibitor (respiratory use) for the treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency.
The sponsor changed name to ZLB Behring GmbH in February 2005 and subsequently to CSL Behring GmbH in April 2007.
EU/3/01/044: Public summary of positive opinion for orphan designation of human alpha1-proteinase inhibitor (respiratory use) for the treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency (PDF/109.94 KB)
First published: 24/02/2009
Last updated: 06/05/2011
Human alpha1-proteinase inhibitor
|Disease / condition||
Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.